Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Free Cash Flow (2016 - 2026)

Heron Therapeutics filings provide 15 years of Free Cash Flow readings, the most recent being -$1.9 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow rose 78.49% to -$1.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$20.9 million, a 9.54% increase, with the full-year FY2025 number at -$27.9 million, down 15.16% from a year prior.
  • Free Cash Flow hit -$1.9 million in Q1 2026 for Heron Therapeutics, up from -$9.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $2.9 million in Q3 2024 to a low of -$45.0 million in Q1 2022.
  • Median Free Cash Flow over the past 5 years was -$10.0 million (2023), compared with a mean of -$15.4 million.
  • The widest YoY moves for Free Cash Flow: up 129.48% in 2024, down 663.17% in 2024.
  • Heron Therapeutics' Free Cash Flow stood at -$37.9 million in 2022, then soared by 105.81% to $2.2 million in 2023, then plummeted by 663.17% to -$12.4 million in 2024, then increased by 26.04% to -$9.2 million in 2025, then soared by 78.97% to -$1.9 million in 2026.
  • The last three reported values for Free Cash Flow were -$1.9 million (Q1 2026), -$9.2 million (Q4 2025), and $1.3 million (Q3 2025) per Business Quant data.